Strategic Benefit Resources acquires OneSource StopLoss


Strategic Benefit Resources (SBR), an Atlanta-based company that partners with employee benefit advisors, third party administrators, and other intermediaries, has acquired OneSource StopLoss (OSSL).

The financial terms of the deal were not disclosed.

Founded in 1996, OneSource StopLoss is a consulting underwriting company based in Elk Grove, California. The company offers risk-based solutions for the protection of the employee and also the employer.

See also  Cityblock Health raises $192m in Series C extension funding round

Jason R. Youngs – OneSource StopLoss President said: “As we celebrated our 25th year of doing business, it was important for us to find like-minded partners who shared our passion for providing best in class stop loss and self-funded broker support services.

“Aligning with SBR broadens our joint capabilities and delivers a unified platform to share our unique culture and unparalleled skills well into the future.”

Strategic Benefit Resources acquires consulting underwriting company OneSource StopLoss

Strategic Benefit Resources acquires consulting underwriting company OneSource StopLoss. Photo courtesy of Tumisu from Pixabay.

Strategic Benefit Resources on the other hand is engaged in offering specialized self-funded health plan expertise, personalized outsourced stop-loss insurance services, and technology-driven solutions.

See also  Construction begins on LyondellBasell’s $2.4bn PO/TBA Plant in Houston

Wayne K. Soud, Jr. – Strategic Benefit Resources President and CEO said: “As Strategic Benefit Resources continues to expand its footprint in the US, establishing a presence on the west coast has been a key initiative to our longer-term growth strategy.

“We are excited to have found a new partner with OneSource StopLoss (OSSL) to plant a flag for SBR on the west coast and continue our growth in the US. There are a lot of similarities and synergies between our two firms, and we look forward to building on OSSL’s success as we continue to expand into the west coast market.”

See also  Aurobindo Pharma announces FDA final approval for Amphotericin B Liposome for Injection
Share This